Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Tenon(R) Medical Reports Fourth Quarter and Full Year 2025 Financial Results

~ Fourth Quarter 2025 Revenue of $1.5 Million, a 92% Increase Compared to Prior Year ~ ~ Record Full Year 2025 Revenue of $3.9 Million, a 20% Increase compared to Prior Year, Driven by Strong Second Half Momentum ~ ~ Record Full Year 2025 Gross Profit of $2.4 Million, a 38% Increase Compared to Prior Year ~ ~ Secured FDA 510(k) Clearance For its Next-Generation SImmetry®+ SI Joint Fusion System ~ ~ Completed Initial SImmetry®+ Procedures at Centers of Excellence, Advancing Commercial Rollout and Supporting Early Surgeon Adoption ~ LOS GATOS, CA / ACCESS Newswire / March 19, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon Medical" or the "Company"), a company redefining care for patients suffering from sacro-pelvic disorders, today reported financial results for the fourth quarter and year ended December 31, 2025. Financial Results and Business Updates Fourth Quarter 2025 Results: Record revenue of $1.5 million, an increase of 92% compared to $0.8 million in the fourth quarter of 2024.

WallachBeth Capital Announces Closing of Tenon Medical, Inc Private Placement of Senior Original Issue Discount Convertible Notes Offering for Gross Proceeds of $4.3 Million

JERSEY CITY, N.J., March 12, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announces the closing of Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), private placement of senior convertible promissory notes with several institutional and high net worth investors for aggregate gross proceeds of $4.3 million before deducting fees of the placement agent.

Tenon Medical Announces Closing of Private Placement of Senior Convertible Notes Offering for Gross Proceeds of $ 4.3 Million

LOS GATOS, CA / ACCESS Newswire / March 12, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacro-pelvic disorders, today announced the closing of a private placement of senior convertible promissory notes with several institutional and high net worth investors for aggregate gross proceeds of $4.3 million before deducting fees of the placement agent. The 20% original issue discount notes have an aggregate principal amount of $4.3 million with a maturity date of September 11, 2026 and are convertible, following the six month anniversary of the issuance date, into shares of the Company's common stock at a conversion price equal to 80% of the VWAP for the three (3) Trading Days immediately prior to the date of conversion, subject to adjustment as provided therein.

Tenon(R) Medical Strengthens Intellectual Property Portfolio with Strategic Patent Expansion

Expanded Global Portfolio Enhances Competitive Position and Supports Long-Term Growth Strategy LOS GATOS, CA / ACCESS Newswire / February 18, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company redefining care for patients suffering from sacro-pelvic disorders, today announced a strategic expansion of its U.S. intellectual property portfolio following receipt of Notices of Allowance from the United States Patent and Trademark Office (USPTO) for multiple patent applications expected to issue in 2026. These newly allowed claims will further strengthen the Company's growing patent portfolio and build upon the (10) ten patents issued in 2025, including (5) five issued by the USPTO and (5) five issued internationally.